Our Products
Our Products

Hertraz

Hertraz

Generic:

Trastuzumab

 

Therapeutic Class:

Antineoplastic Agent

 

Composition:

150 mg and 440 mg multi-dose vial containing powder for concentrate for solution for intravenous infusion. Reconstituted Hertraz concentrate contains 21 mg/mL of trastuzumab, a humanised IgG1 monoclonal antibody expressed in Chinese hamster ovary Cells.

 

Description:

Hertraz (Trastuzumab) is a monoclonal antibody used to treat breast cancer

 

Indications:

Metastatic Breast Cancer:

Hertraz is indicated for the treatment of adult patients with HER2 positive metastatic cancer (MBC).

 

Early Breast Cancer:

Hertraz is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC).

 

Metastatic Gastric Cancer:

Hertraz in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.

 

Dosage:

Three – Weekly Schedule:

The recommended initial loading dose is 8 mg/kg body weight. The recommended maintenance dose at threei ntervals is 6 mg/kg body weight, beginning three weeks after the loading units.

 

Weekly Schedule:

The recommended initial loading dose of trastuzumab is 4 mg/kg body weight. The recommended weekly maintenance dose of trastuzumab is 2 mg/kg body weight, beginning one week after the loading dose.